Patent EP-2011787-A1 (EP)
Title: Dying composition comprising an azomethin-type compound with a pyrazolinone moiety
Inventor: FADLI AZIZ
IPC: C07D231/48
Filed: 2008-06-19
Abstract: Coloring composition comprises, in a dyeing medium, at least one new or known pyrazolinone compound (A) of leuco type (I) and azomethine type (II) and their mesomers, acid addition salts and solvates. Coloring composition comprises, in a dyeing medium, at least one pyrazolinone compound (A) of leuco type of formula (I) and azomethine type of formula (II) and their mesomers, acid addition salts and solvates. n : 0-3; either X : OH or NR1aR1b; and U 1>CR or N; or XU 1>(when X is NHR1a, U 1>is CR, and R is alkoxy) : 6-membered cyclic ring comprising morpholine (optionally substituted by one or more 1-4C alkyl); either R1a, R1b : H, 1-6C alkyl (optionally substituted by one or more OH, 1-2C alkoxy, amino or (di)alkyl(1-2C)amino) or phenyl (optionally substituted by one or more OH, amino or 1-2C alkoxy); or NR1aR1b (when R1a, R1b are not H) : T; T : optionally saturated 5-7 membered heterocycle, where the carbon atom of heterocycle can be replaced by O or N, and the heterocycle is optionally substituted by one or more halo, amino, (di)alkyl(1-4C)amino, OH, carboxy, carboxamido, 1-2C alkoxy or 1-4C alkyl (optionally substituted by one or more OH, amino, (di)alkylamino, alkoxy, carboxy or sulfonyl); R : 1-4C alkyl or 1-4C alkoxy (both optionally substituted by OH), (di)alkyl(1-4C)amino (where alkyl is optionally substituted by OH) or H; either V 1>O, NR1a or N +>R1aR1b, when V 1>is N +>R1aR1b, electroneutrality of (II) is ensured by an An ->; or V 1>U 1>(when V 1>is NR1a, and U 1>is CR) : 6-membered cyclic ring comprising morpholine (optionally substituted by one or more 1-4C alkyl); An ->anion or its mixture; either Y 1>OH, 1-4C (hydroxy)alkyl, halo comprising Cl, I, F or Br, O (substituted by 1-4C alkyl or (hetero)aryl (all substituted by one or more OH)) or NR2aR3a; or Y 1>Y 1>(joined together by two adjacent carbon atoms) : optionally saturated 5-6 membered (hetero)cyclic ring e.g. benzene, pyrrole, pyrrolidine, pyrazole, furan, pyrrolidine, morpholine or imidazole (all optionally substituted by one or more 1-4C alkyl); either R2a, R3a : 1-6C alkyl or phenyl (both optionally substituted by OH, 1-2C alkoxy, amino or (di)alkyl(1-2C)amino), H, 1-4C alkylcarbonyl (optionally substituted by cation, which is nitrogenized heterocyclic ring e.g. imidazole, thiazole, pyridine, piperidine, pyrrolidine, pyrimidine, pyrazine, imidazolium, pyridinium, thiazolium, pyrrolidinium, piperidinium or pyrimidinium (all optionally substituted by 1-4C alkyl) or quaternary ammonium e.g. trialkylammonium) or aminocarbonyl; or NR2aR3a : T; Z : 1-4C alkyl, NR 3>R 4>or OR 5>; either R 1>, R 2>1-6C alkyl (optionally substituted by one or more OR 6>, NR 7>R 8>, carboxy, carboxylate 1-4C alkyl, sulfonic 1-4C alkyl, (di)alkylcarboxamido (CONR 7>R 8>), sulfonamido (SO 2NR 7>R 8>), 5-6 membered heteroaryl or phenyl (optionally substituted by an one or more 1-4C alkyl, OH, 1-2C alkoxy, amino, (di)alkyl(1-2C)amino, hydroxy-1-4C alkyl)), phenyl (optionally substituted by one or more 1-4C alkyl, hydroxy(1-4C)alkyl, OH, 1-2C alkoxy, amino or (di)alkyl(1-2C)amino) or 5-6 membered heteroaryl (optionally substituted by one or more 1-4C alkyl or 1-2C alkoxy); or NR 1>R 2>T 1>; T 1>optionally saturated 5-7 membered heterocyclic ring, where the carbon atom of heterocycle can be replaced by O or N, and the heterocycle is optionally substituted by one or more halo, amino, (di)alkyl(1-4C)amino, (di)hydroxyalkyl(1-4C)amino, OH, carboxy, (di)alkylcarboxamido, 1-2C alkoxy or 1-4C alkyl (optionally substituted by one or more OH, amino, (di)alkylamino, alkoxy, carboxy or sulfonyl); either R 3>-R 5>R 1>or H; or NR 3>R 4>T 1>; R 6>H, 1-4C alkyl (optionally substituted by one or more OH, 1-2C alkoxy, (di)alkylcarboxamido (CONR 9>R 1>0>), sulfonyl (SO 2R 9>) or phenyl (optionally substituted by one or more 1-4C alkyl, OH, 1-2C alkoxy, amino or (di)alkyl(1-2C)amino)) or phenyl (optionally substituted by one or more 1-4C alkyl, OH, 1-2C alkoxy, amino or (di)alkyl(1-2C)amino); R 7>, R 8>R 6>, (di)alkylcarboxamido (CONR 9>R 1>0>) or sulfonyl (SO 2R 9>); and R 9>, R 1>0>H or 1-4C alkyl (optionally substituted by one or more OH or 1-2C alkoxy). Provided that (II) is not [4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylimino)-cyclohexa-2,5-dienylidene]-diethyl-ammonium anion, ethyl-(2-hydroxy-ethyl)-[3-methyl-4 -[(Z)-1,2,5-trimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-ylimino]-cyclohexa-2,5-dien-(E)-ylidene]-ammonium anion, [4-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylimino)-cyclohexa-2,5-dienylidene]-diethyl-ammonium anion, and ethyl-(2-hydroxy-ethyl)-[3-methyl-4-[(Z)-1,2,5-trimethyl-3-oxo-2,3-dihydro-1H-pyrazol-4-ylimino]-cyclohexa-2,5-dien-(E)-ylidene]-ammonium anion and their mesomers, acid addition salts and solvates. Independent claims are included for: (1) new pyrazolinone compounds (A); and (2) a multi-compartment device, or kit for dyeing, comprising first compartment containing (I) and second compartment containing oxidizing agent, and optionally (II) and an alkaline agent. [Image].